Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Smart exercise planning could boost recovery for people with cancer

2.

Disparities in use of MRI to detect prostate cancer: Race and location may influence testing

3.

Why alarm is easing over a rise in pancreatic cancer among the young

4.

FDA OKs Subcutaneous Daratumumab Plus VRd for Myeloma

5.

'Chemo brain' cognitive issues linked to poor lymphatic-system drainage


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot